ArticleNPJ breast cancer2022

Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savings.

Po-Hung Hsieh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.